The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine clesrovimab-cfor (Enflonsia) for preventing respiratory syncytial virus (RSV) in ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

FDA approval of Merck’s RSV antibody drug, Enflonsia, makes it a direct competitor to Sanofi’s Beyfortus. The new Merck product is expected to be discussed by the CDC’s Advisory Committee on ...